Eric A. Adams, MIBS

Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in

Learn More

Jeff Charpentier, CPA, CA

Chief Financial Officer

Mr. Charpentier is a respected veteran of more than 25 years in the biopharmaceutical sector. Mr. Charpentier has held a series of senior financial positions at a number of public and private companies in the pharmaceutical and technology sectors where he led multiple

Learn More

Josh Blacher, MBA

Chief Business Officer

Mr. Blacher joined InMed Pharmaceuticals in 2018, bringing two decades of leadership experience in senior positions within the US healthcare and capital markets sectors, focusing primarily on strategic finance, business development, and managing relations with

Learn More

Alexandra D.J. Mancini, MSc

Senior Vice President, Clinical & Regulatory Affairs

Ms. Mancini has over 30 years of global biopharmaceutical R&D experience, overseeing a wide range of drug development activities, with a particular emphasis on clinical development and regulatory affairs. She has been an executive with numerous biotech

Learn More

Dr. Eric C. Hsu, PhD

Vice President, Pre-Clinical Research & Development

Dr. Hsu joined InMed with over 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affair and Operations.

Learn More

Michael Woudenberg, P.Eng.

Vice President, Chemistry, Manufacturing & Controls

Mr. Woudenberg joined InMed with over 20 years of engineering, leadership and GMP manufacturing and scale up experience with regards to the development, technology transfer and commercialization of active pharmaceutical ingredients (APIs). Prior to joining InMed,

Learn More